Gerresheimer AG Appoints Klaus Rohrig to Supervisory Board, Reflecting Shareholder Structure Changes
TL;DR
Klaus Rohrig's appointment to Gerresheimer's Supervisory Board gives the Active Ownership Group direct influence over the pharmaceutical packaging company's strategic direction.
Klaus Rohrig replaces Dr. Dorothea Wenzel on Gerresheimer's Supervisory Board and Audit Committee to reflect shareholder changes, with formal election scheduled for June 2026.
This leadership transition at Gerresheimer ensures continued oversight of safe drug delivery systems that protect patient health worldwide.
Klaus Rohrig, co-founder of Active Ownership Group, now oversees Gerresheimer's pharmaceutical packaging operations serving 13,600 employees across 16 countries.
Found this article helpful?
Share it with your network and spread the knowledge!
Klaus Rohrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. This board restructuring signals how evolving ownership patterns can directly influence corporate governance at major pharmaceutical packaging companies.
With his appointment, Klaus Rohrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG, placing him in a critical oversight role for the company's financial reporting and compliance functions. The Audit Committee position carries significant responsibility in ensuring transparent financial practices at a time when regulatory scrutiny of pharmaceutical supply chains continues to intensify globally.
Dr. Axel Herberg, Chairman of the Supervisory Board of Gerresheimer AG, acknowledged Dr. Wenzel's contributions, stating that she made a significant contribution to the fulfillment of the committee's duties through her expertise and experience. The transition occurs as Gerresheimer continues to expand its global footprint in pharmaceutical packaging and drug delivery systems.
Klaus Rohrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG's co-determined Supervisory Board, indicating broader potential changes in the company's governance structure. This governance evolution comes as Gerresheimer, with over 40 production sites in 16 countries across Europe, America and Asia, maintains its position as a global partner for the pharma, biotech and cosmetic industries.
The company's comprehensive portfolio includes drug containment solutions, closures and accessories, drug delivery systems, medical devices and solutions for the health industry. Product offerings span digital solutions for therapy support, on-body devices, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules and various containers. More information about the company's operations can be found at https://www.gerresheimer.com.
Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4 billion in 2024 and currently employs approximately 13,600 people worldwide. The leadership change reflects how shareholder dynamics can prompt governance adjustments even at established companies with significant market presence and extensive manufacturing capabilities across multiple continents.
Curated from NewMediaWire
